| Literature DB >> 34183374 |
Anaïs Schaschkow1, Lokman Pang2,3, Valerie Vandenbempt1, Bernat Elvira1, Sara A Litwak3, Beata Vekeriotaite1, Elisa Maillard4,5, Marjorie Vermeersch6, Flavia Mm Paula7, Michel Pinget4,5, David Perez-Morga6, Daniel J Gough7,8, Esteban N Gurzov9,2.
Abstract
Most obese and insulin-resistant individuals do not develop diabetes. This is the result of the capacity of β-cells to adapt and produce enough insulin to cover the needs of the organism. The underlying mechanism of β-cell adaptation in obesity, however, remains unclear. Previous studies have suggested a role for STAT3 in mediating β-cell development and human glucose homeostasis, but little is known about STAT3 in β-cells in obesity. We observed enhanced cytoplasmic expression of STAT3 in severely obese and diabetic subjects. To address the functional role of STAT3 in adult β-cells, we generated mice with tamoxifen-inducible partial or full deletion of STAT3 in β-cells and fed them a high-fat diet before analysis. Interestingly, β-cell heterozygous and homozygous STAT3-deficient mice showed glucose intolerance when fed a high-fat diet. Gene expression analysis by RNA-seq showed reduced expression of mitochondrial genes in STAT3 knocked down human EndoC-βH1 cells and was confirmed in FACS-purified β-cells from obese STAT3-deficient mice. Moreover, silencing of STAT3 impaired mitochondria activity in EndoC-βH1 cells and human islets, suggesting a mechanism for STAT3-modulated β-cell function. We propose STAT3 as a regulator of β-cell function, improving glucose-induced insulin secretion in obesity.Entities:
Year: 2021 PMID: 34183374 DOI: 10.2337/db20-1222
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.461